Clinical Trial Update: First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients [Phase 4]

View source ↗

Summary

Phase 4 update on first-line treatment with olaparib in combination with bevacizumab for HRD-positive ovarian cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Lynparza (olaparib)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Carcinoma, Ovarian Epithelial | Phase 4 | Status: ACTIVE_NOT_RECRUITING